Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099058 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
- 20
- Study locations
NCT02099058 is a Phase 1 study of Advanced Solid Tumors Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 237 participants, below the 328-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02099058, a Phase 1 study of Advanced Solid Tumors Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Nivolumab
- DRUG Erlotinib
- DRUG Telisotuzumab vedotin
Study Locations (20)
California
- City of Hope /ID# 153759 - Duarte
- University of California, Los Angeles /ID# 148295 - Los Angeles
- UC Irvine /ID# 165107 - Orange
- University of California, Davis Comprehensive Cancer Center /ID# 129805 - Sacramento
Illinois
- The University of Chicago Medical Center /ID# 136995 - Chicago
- Ingalls Memorial Hosp /ID# 165876 - Harvey
Massachusetts
- Massachusetts General Hospital /ID# 129804 - Boston
- Dana-Farber Cancer Institute /ID# 168782 - Boston
Michigan
- Duplicate_Henry Ford Health System /ID# 149857 - Detroit
- Herbert Herman Cancer Center /ID# 149858 - Lansing
New York
- Northwell Health - Monter Cancer Center /ID# 218170 - Lake Success
- Montefiore Medical Park at Eastchester /ID# 218445 - The Bronx
Texas
- Mary Crowley Cancer Research /ID# 123760 - Dallas
- University of Texas MD Anderson Cancer Center /ID# 154648 - Houston
Arizona
- Scottsdale Healthcare /ID# 123761 - Scottsdale
Colorado
- Univ of Colorado Cancer Center /ID# 123759 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2014-01-15 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099058
The ClinicalTrials.gov registry entry for NCT02099058 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (28% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 4 interventions - of which Osimertinib is the first listed.
NCT02099058 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02099058 about?
NCT02099058 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors". This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monot...
What is the current status of trial NCT02099058?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2014-01-15. Estimated completion is 2026-08.
What conditions does trial NCT02099058 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT02099058?
The interventions under investigation include: Osimertinib (DRUG), Nivolumab (DRUG), Erlotinib (DRUG), Telisotuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT02099058?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02099058 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.